Hepatitis C Information - Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

Extrahepatic sites may cause rapid recurrence of Hepatitis C after
RxPG - "In most patients HCV RNA levels decreased rapidly during and after transplantation and subsequently began to increase reaching above pre-transplant levels in all but one patient within a few days of the procedure." By AASLD, When a diseased

Chiron partners with Portland's AVI
East Bay Business Times - Emeryville-based Chiron's (NASDAQ: CHIR) scientists were the first to clone HCV, and the company has been granted more than 100 HCV-related patents. In conjunction with the license agreement, Portland-based AVI (NASDAQ: AVII) will issue Chiron shares

SuperGen to buy Montigen Inc.
Contra Costa Times - SuperGen to buy Montigen Inc. SuperGen Inc. (SUPG) said it agreed to acquire privately held oncology drug developer Montigen Pharmaceuticals Inc. for $18 million in cash and stock. Under the terms of the agreement, Dublin-based SuperGen will pay